News for F-star Therapeutics, Inc. (FSTX)

The stem cell market is experiencing positive growth due to several factors, including the increasing prevalence of chronic diseases, the need for drug...

The next-generation complement therapeutics market is experiencing positive growth driven by the rising global incidence of cardiovascular, genetic,...

Advanced melanoma is when melanoma cells spread from where they started (the primary melanoma) to other parts of the body. The advanced melanoma...

Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

Fairfax Financial Holdings portfolio, holdings, 13F and news. Updated: 2023-05-15

-  Horizon Platform Originates $47 Million of New Loans in Q1, Including $40 Million of New Loans for HRZN -  -  Horizon Platform Ends Quarter with Committed Backlog of $218 Million,... | April 12, 2023

/PRNewswire/ -- The bispecific antibodies for cancer market size is forecasted to increase by USD 400.72 million from 2022 to 2027, at a CAGR of 8.82%,...

By Colin Kellaher Shares of F-star Therapeutics Inc. jumped more than 15% after U.S. regulators finally approved the acquisition of the clinical-stage biopharmaceutical company by a unit of... | March 7, 2023

Current national security tensions could put F-star's acquisition by Sino Biopharmaceutical at significant risk. Here's what investors in FSTX stock need to know.

FSTX seems undervalued, even at the $7.12 takeover bid. CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. Read more here.

LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX...

Merger arbitrage spreads are wide and there are plenty of opportunities with spreads of up to 81%. Click here to read our latest analysis of these deals.

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | December 29, 2022

/PRNewswire/ -- In the bispecific antibodies for cancer market, emerging bispecific antibody generation platforms will be a key trend during the forecast...

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

BALA CYNWYD, Pa., June 23, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...

/PRNewswire/ -- According to the market analysis report "Bispecific Antibodies for Cancer Market by Type and Geography - Forecast and Analysis 2022-2026", the...

F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today... | November 10, 2021